A LC-MS-MS method for determination of low doxazosin concentrations in plasma after oral administration to dogs

Journal of Chromatographic Science

Volumn 48, Issue 2, 2010, Pages 114-119

  Erceg, Marijana ^a   Cindric, Mario ^b   Frketic, Lidija Pozaic ^a   Vertzoni, Maria ^c   Cetina Cižmek, Biserka ^a   Reppas, Christos ^c  

^a PLIVA CROATIA LTD   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 75849156610     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/48.2.114     Document Type: Article

References (26)

1. K.S. Babamoto and W.T. Hirokawa. Drug Review: Doxazosin: A new a1-adrenergic antagonist. Clin. Pharm. 11: 415-425 (1992).
2. H.L. Elliot, P.A. Meredith, and J.L. Reid. Pharmacokinetic overview of Doxazosin. Am. J. Cardiol. 59: 78G-81G (1987).
3. R.V. Carlson, R.R. Bailey, E.J. Begg, M.G. Cowlishaw, and J.R. Sharman. Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin. Pharmacol. Ther. 40(5): 561-566 (1986).
4. M.G. Cowlishaw and J.R. Sharman. Doxazosin determination by high-performance liquid chromatography using fluorescence detection. J. Chromatogr. 344: 403-407 (1985).
5. H.G. Fouda, T.M. Twomey, and R.P. Schneider. Liquid chromatography analysis of doxazosin in human serum with manual and robotic sample preparation. J.Chromatogr.Sci.26: 570-573 (1988)
6. G.P. Jackman, F. Colagrande, and W.J. Louis. Validation of a solid-phase extraction high-performance liquid chromatographic assay for doxazosin. J. Chromatogr. 566: 234-238 (1991).
7. P. Sripalakit, P. Nermhom, and A. Saraphanchotiwitthaya. Improvement of doxazosin determination in human plasma using high-performance liquid chromatography with fluorescence detection. J. Chromatogr. Sci. 43: 63-66 (2005).
8. P. Sripalakit, P. Nermhom, and A. Saraphanchotiwitthaya. Validation and pharmacokinetic application of a method for deter-mination of doxazosin in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 20: 729-735 (2006).
9. Y.J. Kim, Y. Lee, M.J. Kang, J.S. Huh, M. Yoon, J. Lee, and Y.W. Choi. High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. Biomed. Chromatogr. 20: 1172-1177 (2006).
10. Y.H. Kwon, H.S. Gwak, S.J. Yoon, and I.K. Chun. Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration inKorean healthy volunteers. Drug.Dev.Ind.Pharm. 33: 824-829 (2007).
11. X. Wei, J. Yin, G. Yang, C. He, and Y Chen. On-line solid-phase extraction with a monolithic weak cation-exchange column and simultaneous screening of alpha1-adrenergic receptor antagonists in human plasma. J. Sep. Sci. 30: 2851-2857 (2007).
12. N. Ma, W. Liu, H. Li, B. Chen, Y. Zhu, X. Liu, F. Wang, D. Xiang, and B. Zhang. LC-MS determination and relative bioavailability of dox-azosin mesylate tablets in healthy Chinese male volunteers. J. Pharm. Biomed. Anal. 43: 1049-1056 (2007).
13. O.Y. Al-Dirbashi, H.Y. Aboul-Enein, M. Jacob, and K.M.S. Al-Qahtani. UPLC-MS/MS determination of doxazosine in human plasma. Anal. Bioanal. Chem. 385: 1439-1443 (2006).
14. H.Y. Ji, E.J. Park, K.C. Lee, and H.S. Lee. Quantificationof doxazosin in human plasma using hydrophilic interaction liquid chromatog-raphy with tandem mass spectrometry. J Sep Sci. 31(9): 1628-1633 (2008).
15. L. Conway, J.J. McNeil, J. Hurley, G.P. Jackman, H. Krum, L.G. Howes, and W.J. Louis. The effects of food on the oral bioavail-ability of doxazosin in hypertensive subjects. Drug.Invest.6: 90-95 (1993).
16. P. Macheras, C. Reppas, and J.B. Dressman. Biopharmaceutics of orally administered drugs. Ellis Horwood Limited, 1995, ISBN0-13-108093-8, pp 89-123 (Chapter 5).
17. J.M. Green. A Practical Guide to Analytical Method Validation. Anal. Chem. 68: 305A-309A (1996).
18. V.P. Shah, K.K. Midha, J.W.A. Findlay, H.M. Hill, J.D. Hulse, I.J. McGilveray, G. McKay, K.J. Miller, R.N. Patnaik, M.L. Powell, A. Tonelli, C.T. Viswanathan, and A. Yacobi. Workshop/conference report-bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17: 1551 (2000).
19. J.C. Miller and J.N. Miller. Statistics for Analytical Chemistry, Wiley, NY, 1984, pp. 90-98 (Chapter 4).
20. M.L. Chen, L. Lesko, and R.L. Williams. Measures of exposure versus measures of rate and extent of absorption. Clin. Pharmacokinet. 40(8): 565-572 (2001).
21. J.C. Erve, S.C. Vashishtha, W. DeMaio, and R.E. Talaat. Metabolism of prazosin in rat, dog, and human liver microsomes and cryopre-served rat and human hepatocytes and characterization of metabo-lites by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos. 35(6): 908-916 (2007).
22. L.L. De Zwart, C.J.M. Rompelberg, A.J.A.M. Sips, J. Welink, and J.G.M. Van Engelen. National Institute of Public Health and the Environment, RIVM Report 623860010, Bilthoven, Netherlands, 1999. http://www.rivm.nl/bibliotheek/rapporten/623860010.html. Date accessed: 28 January, 2009.
23. E. Nelson, E.L. Knoechel, W.E. Hamlin, and J.G. Wagner. Influence of the absorption rate of tolbutamide on the rate of decline of blood sugar levels in normal humans. J. Pharm. Sci. 51: 509-514 (1962).
24. S. Furesz. Blood levels following oral administration of different preparations of novobiocin. Antibiotics and Chemotherapy 8: 446-449 (1958).
25. S.L. Lin, L. Lachman, C.J. Swartz, and C.F. Huebner. Preformulation investigation. I. Relation of salt forms and biological activity of an experimental antihypertensive. J. Pharm. Sci. 61(9): 1418-1422 (1972).
26. R.K. Verbeeck, I. Kanfer, and R.B. Walker. Generic substitution: The use of medicinal products containing different salts and implications for safety and efficacy. Eur. J. Pharm. Sci. 28(1-2): 1-6 (2006).